Technical Analysis for ORIC - Oric Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 8.06% | |
| Volume Surge | Other | 8.06% | |
| NR7 | Range Contraction | 8.06% | |
| Inside Day | Range Contraction | 8.06% | |
| Wide Bands | Range Expansion | 8.06% | |
| Oversold Stochastic | Weakness | 8.06% | |
| Slingshot Bearish | Bearish Swing Setup | 10.56% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 5 hours ago |
| Up 5% | about 6 hours ago |
| 60 Minute Opening Range Breakout | about 6 hours ago |
| Up 3% | about 10 hours ago |
| Up 2% | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/08/2024
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.63 |
| 52 Week Low | 5.27 |
| Average Volume | 507,890 |
| 200-Day Moving Average | 9.21 |
| 50-Day Moving Average | 8.47 |
| 20-Day Moving Average | 7.75 |
| 10-Day Moving Average | 7.10 |
| Average True Range | 0.52 |
| RSI (14) | 46.24 |
| ADX | 28.59 |
| +DI | 20.85 |
| -DI | 23.97 |
| Chandelier Exit (Long, 3 ATRs) | 7.80 |
| Chandelier Exit (Short, 3 ATRs) | 7.90 |
| Upper Bollinger Bands | 9.33 |
| Lower Bollinger Band | 6.18 |
| Percent B (%b) | 0.46 |
| BandWidth | 40.63 |
| MACD Line | -0.51 |
| MACD Signal Line | -0.54 |
| MACD Histogram | 0.0228 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.75 | ||||
| Resistance 3 (R3) | 8.64 | 8.16 | 8.57 | ||
| Resistance 2 (R2) | 8.16 | 7.88 | 8.22 | 8.50 | |
| Resistance 1 (R1) | 7.90 | 7.70 | 8.03 | 8.01 | 8.44 |
| Pivot Point | 7.42 | 7.42 | 7.49 | 7.48 | 7.42 |
| Support 1 (S1) | 7.16 | 7.14 | 7.29 | 7.27 | 6.84 |
| Support 2 (S2) | 6.68 | 6.96 | 6.74 | 6.78 | |
| Support 3 (S3) | 6.42 | 6.68 | 6.72 | ||
| Support 4 (S4) | 6.53 |
